Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2014; 20(16): 4526-4535
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4526
Table 1 Interpretation and scoring of human epidermal growth factor receptor 2 immunohistochemistry for gastric cancer, as approved by the United States Food and Drug Administration in relation to the HercepTest (Dako)
ScoreSurgical specimen staining patternBiopsy specimen staining patternHER2 overexpression assessment
0No reactivity or membranous reactivityin < 10% of tumor cellsNo reactivity or no membranous reactivity in any (or < 5 clustered) tumor cellsNegative
1+Faint/barely perceptible membranous reactivity in ≥ 10% of tumor cells; cells are reactive only in part of their membraneTumor cell cluster (≥ 5 cells) with a faint/barely perceptible membranous reactivity irrespective of percentage of tumor cells stainedNegative
2+Weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cellsTumor cell cluster (≥ 5 cells) with a weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stainedEquivocal
3+Strong complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cellsTumor cell cluster (≥ 5 cells) with a strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stainedPositive

Citation: Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535